


CDFI

| | | | |
|--------------------|---|-------|----------|
| Cat. No.: | HY-156009 | | |
| CAS No.: | 1199797-92-6 | | |
| Molecular Formula: | C ₂₈ H ₂₈ ClFN ₂ | | |
| Molecular Weight: | 446.99 | | |
| Target: | Others | | |
| Pathway: | Others | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (223.72 mM; Need ultrasonic)

| Concentration | Solvent | Mass | | |
|---------------------------|---------|-----------|------------|------------|
| | | 1 mg | 5 mg | 10 mg |
| Preparing Stock Solutions | 1 mM | 2.2372 mL | 11.1859 mL | 22.3719 mL |
| | 5 mM | 0.4474 mL | 2.2372 mL | 4.4744 mL |
| | 10 mM | 0.2237 mL | 1.1186 mL | 2.2372 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: 2.5 mg/mL (5.59 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: 2.5 mg/mL (5.59 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

CDFI is an inhibitor of the lipid II flippase MurJ. CDFI potentiates the activity of β -lactams against MRSA^{[1][2]}.

REFERENCES

- Fernandes PB, et al. Revisiting the Role of VraTSR in Staphylococcus aureus Response to Cell Wall-Targeting Antibiotics. J Bacteriol. 2022 Aug 16;204(8):e0016222.
- Dhanda G, et al. Antibiotic Adjuvants: A Versatile Approach to Combat Antibiotic Resistance. ACS Omega. 2023 Mar 14;8(12):10757-10783.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA